Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.MNMD · Entity 3884 | Executive President | August 21, 2024 | August 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date August 21, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 202,405 |
Ending reported balance
After 2024-08-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-21 · Exercise / conversion · Acquired 50,000 · Balance 235,000 F1: Exercise of Reporting Person's stock option that would otherwise expire February 27, 2025. Row 2 · 2024-08-21 · Tax withholding · Disposed 32,595 · Balance 202,405 F2: Transaction represents a "net exercise" of an outstanding stock option to purchase an aggregate of 50,000 common shares of the Issuer granted on February 27, 2020. The Reporting Person received 17,405 common shares of the Issuer on the net exercise of the stock option. The Issuer withheld 32,595 common shares underlying the stock option for payment of the exercise price and tax withholding using a stock price of $6.17, which represents the closing price of the Issuer's common shares on August 20, 2024, the day before the exercise. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2025-02-27 | Direct | 0 |
Reported balance
After 2024-08-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-21 · Exercise / conversion · Disposed 50,000 · Balance 0 F3: Represents the option to purchase 50,000 common shares of the Issuer, which vested over a period of four years following the date of the grant of February 27, 2020. All such options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercise of Reporting Person's stock option that would otherwise expire February 27, 2025.
F2: Transaction represents a "net exercise" of an outstanding stock option to purchase an aggregate of 50,000 common shares of the Issuer granted on February 27, 2020. The Reporting Person received 17,405 common shares of the Issuer on the net exercise of the stock option. The Issuer withheld 32,595 common shares underlying the stock option for payment of the exercise price and tax withholding using a stock price of $6.17, which represents the closing price of the Issuer's common shares on August 20, 2024, the day before the exercise.
F3: Represents the option to purchase 50,000 common shares of the Issuer, which vested over a period of four years following the date of the grant of February 27, 2020. All such options are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0000950170-24-099872 · ownership.xml · derivative · entry 3 Halperin Wernli Miri · CIK 0001897615 · Executive President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents the option to purchase 50,000 common shares of the Issuer, which vested over a period of four years following the date of the grant of February 27, 2020. All such options are fully vested. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Tax withholdingCommon Shares | 32,595 | $6.17 | $201,111.15 |
DisclosureSEC source: 0000950170-24-099872 · ownership.xml · nonDerivative · entry 2 Halperin Wernli Miri · CIK 0001897615 · Executive President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,405 F2 · shares: Transaction represents a "net exercise" of an outstanding stock option to purchase an aggregate of 50,000 common shares of the Issuer granted on February 27, 2020. The Reporting Person received 17,405 common shares of the Issuer on the net exercise of the stock option. The Issuer withheld 32,595 common shares underlying the stock option for payment of the exercise price and tax withholding using a stock price of $6.17, which represents the closing price of the Issuer's common shares on August 20, 2024, the day before the exercise. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:30 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | Exercise / conversionCommon Shares | 50,000 | $3.70 | $185,000.00 |
DisclosureSEC source: 0000950170-24-099872 · ownership.xml · nonDerivative · entry 1 Halperin Wernli Miri · CIK 0001897615 · Executive President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of Reporting Person's stock option that would otherwise expire February 27, 2025. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:45 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0000950170-24-023205 · ownership.xml · derivative · entry 1 Wernli Miri Halperin · CIK 0001897615 · Executive President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2034-02-26 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| March 14, 2023 Filed Mar 17, 2023 22:39 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019893 · doc4.xml · nonDerivative · entry 1 Wernli Miri Halperin · CIK 0001897615 · Director · Executive President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 14, 2023 Filed Apr 24, 2023 23:33 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantCommon Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025475 · doc4a.xml · nonDerivative · entry 1 Wernli Miri Halperin · CIK 0001897615 · Director · Executive President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:24 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 780,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-22-021391 · doc4.xml · derivative · entry 2 Wernli Miri Halperin · CIK 0001897615 · Director · Executive President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,462,500 Underlying: Subordinate Voting Shares · 780,000 shares Expires 2022-03-23 F2 · derivative.exercise_price: The option grant has an exercise price of $1.48 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable with 1/48th of the total shares vesting monthly over 48 months from the vesting commencement date, March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:24 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021391 · doc4.xml · nonDerivative · entry 1 Wernli Miri Halperin · CIK 0001897615 · Director · Executive President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in 48 equal monthly installments beginning on April 24, 2022, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.